Compare AbCellera Biologics Inc (ABCL) vs Open Text Corporation (OTEX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Open Text Corporation — how do they compare? AbCellera Biologics Inc trades at $7.23 (market cap $2.35B), while Open Text Corporation trades at $22.6 (market cap $5.65B). The key difference: Open Text Corporation is far larger — about 2.4× AbCellera Biologics Inc's market cap, and Open Text Corporation pays a 4.72% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | OTEX | |
|---|---|---|
Market Cap | $2.35B | $5.65B |
Sector | Health | Technology |
52-Week High | $8.12 | $39.69 |
52-Week Low | $2.78 | $20.01 |
Enterprise Value | $1.99B | $10.81B |
Dividend Yield | — | 4.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
OTEX trades at $22.57, down 2.04% on the day, with a bearish technical signal. The stock shows strong fundamentals with a P/E of 10.95 and net income margin of 9.91%, supported by recent earnings beats. Recent news highlights strategic investments in AI and sovereign cloud in Europe, alongside a dividend payment scheduled for June 19, 2026.
The outlook is mixed; analyst consensus targets $29.75 (31.8% upside) with 42% buy ratings, but technical indicators suggest near-term pressure. Risks include execution of growth initiatives and market volatility. The stock presents a value opportunity if AI investments drive future earnings growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Open Text Corporation
Open Text Corporation is a global leader in Enterprise Information Management (EIM) software and solutions. The company provides a comprehensive platform that helps organizations manage, secure, and leverage their unstructured digital content, including documents, emails, and media files. OTEX's offerings span content management, business process management, customer experience management, and security, serving large enterprises across various industries worldwide.
Read more on OTEX →
